Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

Joseph M. Rocco, Joseph H. Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair, Bita Shakoory, Thomas Robertson, Rachel Dileo, Max W Jacobs, Christa Zerbe, Rachael Gordon, Michael Joseph Ombrello, Amanda K Ombrello, Nirali N Shah, Dimana Dimitrova, Jennifer A Kanakry, Andrew D. Zelenetz, Alison J Moskowitz, Robert N Stuver, Zachary D Epstein-Peterson, Paola Ghione, Elena Mead, Zainab Shahid, Sergio A. Giralt, Sandeep S Raj, Jae H Park, Ivan Maillard, Mark B. Geyer, Wenbin Xiao, Ahmet Dogan, Megan S Lim, Jeffrey I. Zwicker, Jodi V. Mones, Rehka Parameswaran, Lauren G Banaszak, Shamir Geller, Bianca D. Santomasso, Roni Shouval, Kevin J. Curran, Ottavia M Delmonte, Luigi D Notarangelo, Jeffrey I Cohen, Steven M. Holland, Gilles A. Salles, Steven M Horwitz, Santosha A Vardhana, Miguel-Angel Perales, Daniella Schwartz, Irini Sereti, William T. Johnson

Blood blood.2025030976.

https://doi.org/10.1182/blood.2025030976

Published: 2025

Includes: Supplemental data

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 888.

https://doi.org/10.1182/blood-2025-888

Published: 2025

Journal Articles

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Blood (2025) 146 (Supplement 1): 150.

https://doi.org/10.1182/blood-2025-150

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Blood (2025) 146 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2025-1008

Published: 2025

Journal Articles

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Blood (2025) 146 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2025-1766

Published: 2025

Journal Articles

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Blood (2025) 146 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2025-1811

Published: 2025

Journal Articles

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Zachary Epstein-Peterson, Nivetha Ganesan, Ellie Casper, Tiffany Chang, Ahmet Dogan, Ozgur Can Eren, Natasha Galasso, Paola Ghione, Kelly Hannigan, Varun Iyengar, William Johnson, Jason Krastein, Katie Ksanznak, Alison Moskowitz, Brittney Munayiri, Benedetta Sordi, Robert Stuver, Jasmine Zain, Steven Horwitz

Blood (2025) 146 (Supplement 1): 5412.

https://doi.org/10.1182/blood-2025-5412

Published: 2025

Journal Articles

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Blood (2025) 146 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2025-5410

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Mika Geva, Michelle Okwali, Lorenzo Falchi, Ahmet Dogan, Shenon Sethi, Alexander Boardman, Paul Hamlin, Paola Ghione, Colette Owens, Gilles Salles, Lia Palomba, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2025-5374

Published: 2025

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Blood (2025) 146 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2025-3573

Published: 2025

Journal Articles

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Blood (2025) 146 (Supplement 1): 463.

https://doi.org/10.1182/blood-2025-463

Published: 2025

Journal Articles

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Blood (2025) 146 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2025-3605

Published: 2025

Journal Articles

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Blood (2025) 146 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2025-1971

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in CTCL and patients symptoms and outcomes.

Blood (2025) 146 (Supplement 1): 1880.

https://doi.org/10.1182/blood-2025-1880

Published: 2025

Journal Articles

US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed/Refractory third-line or later diffuse large B-cell lymphoma: A comparison of axicabtagene ciloleucel with bispecific antibodies

Olalekan Oluwole, Jennifer Benner, Madhu Palivela, Katalin Bognar, Nicholas Adair, Laura Cianciolo, Matthew Sussman, Markqayne Ray, Paola Ghione

Blood (2025) 146 (Supplement 1): 6194.

https://doi.org/10.1182/blood-2025-6194

Published: 2025

Journal Articles

Characterization of Skin Response in Patients with Mycosis Fungoides and Sezary Syndrome Treated with Mogamulizumab: A Retrospective, Real World Cohort

Rachel Christensen, Robert Stuver, Stephen Dusza, Zachary D. Epstein-Peterson, Paola Ghione, Steven Horwitz, William T. Johnson, Alison Moskowitz, Patricia Myskowski, Melissa Pulitzer, Shamir Geller

Blood (2024) 144 (Supplement 1): 7790.

https://doi.org/10.1182/blood-2024-210327

Published: 2024

Journal Articles

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Blood (2024) 144 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2024-210657

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Detection of intratumoral microorganisms in CTCL and patients symptoms and outcomes.

US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed/Refractory third-line or later diffuse large B-cell lymphoma: A comparison of axicabtagene ciloleucel with bispecific antibodies

Characterization of Skin Response in Patients with Mycosis Fungoides and Sezary Syndrome Treated with Mogamulizumab: A Retrospective, Real World Cohort

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only